An observational study on interaction between 5ASA and thiopurine in ulcerative colitis

An observational study on interaction between 5ASA and thiopurine in ulcerative colitis - An observational study on interaction between 5ASA and thiopurine in ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032775

Enrollment

Registered

2018-05-30

Start date

2017-11-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who diagnosed UC by Ministry of Health, Labor and Welfare Diagnostic criteria of research group on intractable inflammatory bowel disorder (revised version of 2016) Patients who obtained informed consent of this clinical study Patients 18 years of age or older Patients who use both mesalazine and thiopurine Patients who use thiopurine for 8 weeks or more, and have continued for the same amount for 4 weeks or more Patients who have continued the same amount of mesalazine for 4 weeks or more Patients who switch mesalazine formulations to other mesalazine drugs

Exclusion criteria

Exclusion criteria: Patients after total colonectomy Patients who are concurrently using uric acid synthesis inhibitors

Design outcomes

Primary

Measure	Time frame
Changes in blood 6-TGN concentration before and after changing the type of mesalazine	—

Secondary

Measure	Time frame
Clinical efficacy and safety by changing the type of mesalazine	—

Countries

Japan

Contacts

Public ContactHiromu Morikubo

Kitasato University Kitasato Institute Hospital Center for Advanced IBD Research and Treatment

tomato0112@gmail.com03-3444-6161

Outcome results